Harvest Fund Management Co. Ltd Has $18.99 Million Stock Position in Eli Lilly and Company $LLY

Harvest Fund Management Co. Ltd grew its position in Eli Lilly and Company (NYSE:LLY) by 134.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 17,666 shares of the company’s stock after purchasing an additional 10,131 shares during the period. Eli Lilly and Company accounts for 0.7% of Harvest Fund Management Co. Ltd’s investment portfolio, making the stock its 23rd biggest holding. Harvest Fund Management Co. Ltd’s holdings in Eli Lilly and Company were worth $18,987,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. J.W. Cole Advisors Inc. grew its stake in shares of Eli Lilly and Company by 0.9% during the fourth quarter. J.W. Cole Advisors Inc. now owns 26,136 shares of the company’s stock worth $28,088,000 after purchasing an additional 241 shares during the period. Convergence Financial LLC grew its stake in shares of Eli Lilly and Company by 1.3% during the fourth quarter. Convergence Financial LLC now owns 4,456 shares of the company’s stock worth $4,788,000 after purchasing an additional 58 shares during the period. Argent Advisors Inc. grew its stake in shares of Eli Lilly and Company by 4.4% during the fourth quarter. Argent Advisors Inc. now owns 4,441 shares of the company’s stock worth $4,773,000 after purchasing an additional 187 shares during the period. Curio Wealth LLC grew its stake in shares of Eli Lilly and Company by 5.9% during the fourth quarter. Curio Wealth LLC now owns 428 shares of the company’s stock worth $461,000 after purchasing an additional 24 shares during the period. Finally, Avise Financial Cooperative Inc. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $416,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LLY shares. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. The Goldman Sachs Group reissued a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Berenberg Bank boosted their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research note on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,125.00 on Friday. The firm has a market cap of $1.06 trillion, a price-to-earnings ratio of 39.96, a price-to-earnings-growth ratio of 1.18 and a beta of 0.53. The stock’s 50-day moving average is $970.24 and its 200-day moving average is $1,012.19. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,149.10. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly signed a collaboration and licensing deal with Ascidian Therapeutics worth up to $1.9 billion to develop RNA-based kidney-disease therapies, reinforcing its strategy of using GLP-1 cash flow to broaden the pipeline. Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
• Positive Sentiment: Management signaled that more M&A may be coming, which investors view as a way to reduce reliance on obesity drugs and build new long-term growth engines. Eli Lilly’s top dealmaker says don’t be surprised to see more M&A that pushes Lilly into new areas
• Positive Sentiment: Multiple articles highlighted Lilly as a stock to own, citing its strong GLP-1 franchise and broader pipeline momentum across gene editing, vaccines, and cancer. 3 Reasons Eli Lilly Remains a Buy
• Neutral Sentiment: Weight Watchers expanded access to its program through LillyDirect, which reinforces Lilly’s ecosystem around GLP-1 drugs but is not a direct financial catalyst on its own. Weight Watchers Expands Reach Through LillyDirect Partnership (WW)
• Neutral Sentiment: Technical/market commentary also turned favorable, with one note saying Lilly flashed two buy signals, adding to the bullish sentiment around the name. Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals
• Negative Sentiment: Broader market weakness from a selloff in AI/tech sentiment could create some cross-asset pressure, though this is not specific to Lilly’s fundamentals. Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.